Quick Answer
C4 Therapeutics, Inc. reported Common Stock Shares Outstanding of 96.91 million shares for the year ending 2025.
- C4 Therapeutics, Inc. showed an increase of +37.2% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: 1.63 million shares | Q1 2021: 43.11 million shares | Q2 2021: 48.38 million shares | Q3 2021: 48.59 million shares | Q1 2022: 48.75 million shares | Q2 2022: 48.88 million shares | Q3 2022: 48.95 million shares | Q1 2023: 49.05 million shares | Q2 2023: 49.07 million shares | Q3 2023: 49.26 million shares | Q1 2024: 68.78 million shares | Q2 2024: 68.82 million shares | Q3 2024: 70.56 million shares | Q1 2025: 70.99 million shares | Q2 2025: 71.01 million shares | Q3 2025: 74.17 million shares.
- Over the full 7 years of available data (2019 to 2025), C4 Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 6,693.2%.
- Historical annual values: Fiscal year 2025: 96.91 million shares | Fiscal year 2024: 70.63 million shares | Fiscal year 2023: 60.47 million shares | Fiscal year 2022: 48.97 million shares | Fiscal year 2021: 48.69 million shares | Fiscal year 2020: 43.06 million shares | Fiscal year 2019: 1.43 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: